Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Phase 2 | terminated | Jun 22, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With… | Phase 1 | withdrawn | Apr 11, 2011 | Fox Chase Cancer Center | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. | Enrollment / accrual |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous… | Phase 2 | terminated | Aug 21, 2017 | Celldex Therapeutics | Sponsor decision based on emerging risk-benefit profile | Sponsor / business decision |
| NCT03019588 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian… | Phase 3 | terminated | Jan 12, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With… | Phase 2 | terminated | Jan 23, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor closed study | Other (stated, no rule matched) |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Nov 2, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment, Innovent Biologics has decided not to… | Sponsor / business decision |
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | Phase 1 / Phase 2 | terminated | Jul 26, 2019 | Sensei Biotherapeutics, Inc. | Terminated by the sponsor | Other (stated, no rule matched) |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Early Phase 1 | terminated | Mar 2, 2021 | Jonsson Comprehensive Cancer Center | Withdrawn by sponsor | Other (stated, no rule matched) |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | Phase 2 | withdrawn | Dec 15, 2021 | OHSU Knight Cancer Institute | Not feasible at this time. | Other (stated, no rule matched) |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With… | Early Phase 1 | terminated | Oct 21, 2015 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal… | Phase 1 / Phase 2 | terminated | May 13, 2016 | Calithera Biosciences, Inc | lack of efficacy | Efficacy / futility |
| NCT04635527 | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE)… | Phase 1 | terminated | Nov 19, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue… | Sponsor / business decision |
| NCT05338125 | Electrophysiology of the Human Pituitary Gland | N/A | terminated | Apr 20, 2022 | Leiden University Medical Center | too busy for recruitment | Enrollment / accrual |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma,…(PUTNET) | Phase 2 | withdrawn | Feb 19, 2020 | Excel Diagnostics and Nuclear Oncology Center | No subjects were eligible for the study. The study closed on 07-15-2021. | Other (stated, no rule matched) |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer… | Phase 2 | terminated | Sep 28, 2016 | National Cancer Institute (NCI) | Low accrual combined with expiration of study drug | Enrollment / accrual |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT04649671 | The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With… | N/A | terminated | Dec 2, 2020 | Samsung Medical Center | Difficulty in recruitment and deficit of research fund | Enrollment / accrual |
| NCT03906526 | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination… | Phase 1 | terminated | Apr 8, 2019 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | Phase 3 | terminated | Feb 24, 2023 | Timothy Hoffman | The investigational product was approved by the FDA (12/20/2021) and is now commercially available | Other (stated, no rule matched) |
| NCT03137693 | Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | N/A | terminated | May 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | no responders/lack of efficacy | Efficacy / futility |
| NCT02899325 | FDGal PET/CT to Detect Hepatocellular Carcinoma | — | withdrawn | Sep 14, 2016 | British Columbia Cancer Agency | PIs will not pursue trial due to staff and time constraints | Other (stated, no rule matched) |
| NCT04915144 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | Phase 2 | withdrawn | Jun 7, 2021 | British Columbia Cancer Agency | Investigator decision | Investigator |
| NCT03707925 | Bronchoscopic Laser Ablation of Peripheral Lung Tumors | N/A | terminated | Oct 16, 2018 | M.D. Anderson Cancer Center | Very slow accrual rate | Enrollment / accrual |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | Phase 2 | withdrawn | Jul 16, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT05592197 | Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT | N/A | withdrawn | Oct 24, 2022 | Sun Yat-sen University | This is a sub-study of another one. | Other (stated, no rule matched) |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Phase 2 | terminated | Nov 15, 2016 | Alliance Foundation Trials, LLC. | Lack of enrollment | Enrollment / accrual |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | — | terminated | Jan 13, 2016 | CENTOGENE GmbH Rostock | Study no longer pursued. | Other (stated, no rule matched) |
| NCT04713202 | Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior…(NET-PACS) | Phase 2 | withdrawn | Jan 19, 2021 | Chandrikha Chandrasekhara | Funder decision | Other (stated, no rule matched) |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | Phase 2 | terminated | Mar 29, 2016 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid… | Phase 1 | terminated | Jul 15, 2016 | Calithera Biosciences, Inc | Insufficient efficacy of drug; no safety concern | Safety / toxicity |
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced… | Phase 3 | terminated | Aug 2, 2017 | Beijing Shenogen Biomedical Co., Ltd | Because the clinical development plan has been changed. | Other (stated, no rule matched) |
| NCT03240679 | Endoscopic Mucosal Resection and Cellular Matrix | N/A | terminated | Aug 7, 2017 | Mayo Clinic | Difficulty obtaining investigational product and study support. | Other (stated, no rule matched) |
| NCT03671304 | Mobile Intervention - Physical Activity in Cancer Treatment | N/A | terminated | Sep 14, 2018 | University of Texas Southwestern Medical Center | The study was prematurely discontinued, the application utilized with the fitbit is no longer being… | Other (stated, no rule matched) |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal… | Phase 2 | terminated | Aug 16, 2017 | Peking University | Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal… | Other (stated, no rule matched) |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+… | Phase 2 | terminated | Aug 12, 2020 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas(STARRS) | Phase 2 | terminated | Aug 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges and availability of other options for lung cancer patients. The… | Safety / toxicity |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be… | Phase 2 | terminated | Jan 20, 2016 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | Phase 1 / Phase 2 | withdrawn | Nov 28, 2022 | Guangdong GD Kongming Biotech LLC | COVID1-19 pandemic | COVID-19 / pandemic |
| NCT04447014 | Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) | — | terminated | Jun 25, 2020 | National Cancer Institute (NCI) | To avoid the duplication of resources and effort associated with the PI switching branches. | Other (stated, no rule matched) |
| NCT04488263 | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | — | terminated | Jul 27, 2020 | National Cancer Institute (NCI) | To avoid the duplication of effort and resources associated with the PI's branch change. | Other (stated, no rule matched) |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of… | Phase 2 | terminated | May 20, 2015 | Rain Oncology Inc | Lack of efficacy | Efficacy / futility |
| NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Jul 11, 2018 | TaiRx, Inc. | The study has been terminated due to slow enrollment | Enrollment / accrual |
| NCT04088500 | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced… | Phase 2 | terminated | Sep 12, 2019 | Bristol-Myers Squibb | Slow accrual | Enrollment / accrual |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E… | Phase 1 | terminated | Aug 5, 2019 | University of California, San Francisco | Sponsor funding | Funding |
| NCT03666819 | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone… | Phase 2 | withdrawn | Sep 12, 2018 | Mayo Clinic | Manufacturer will not be supporting this study | Drug supply |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple… | Early Phase 1 | withdrawn | Jan 30, 2020 | Mayo Clinic | study was dropped | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Apr 5, 2023source: clinicaltrials